The pharmaceutical giant Johnson & Johnson has agreed to pay $2.2 billion to settle a long-running probe into its marketing of drugs for unapproved uses. Johnson & Johnson, and subsidiary Janssen Pharmaceuticals, promoted the anti-psychotic drug Risperdal for treating anxiety in elderly dementia patients and behavior problems in children. The company also acknowledged paying kickbacks to Omnicare, the country’s largest pharmacy serving nursing home patients. The $2.2 billion fine marks one of the largest healthcare fraud settlements in U.S. history.